Surgical Resection of Thymoma Still Represents the First Choice of Treatment

Abstract

Objective The aim of this study was to analyze the clinicopathological factors, treatment strategies and survival rates after surgical resection of thymoma.

Methods Between 12/1997 and 5/2010, 42 patients underwent surgical resection of the thymus. The presence of a thymoma was determined by histological examination in 23 patients, while patients with hyperplasia of the thymus (n = 19) were excluded from further analysis.

Results Myasthenia gravis coexisted in 9/23 (39.1%) patients. Thymomas were classified according to the Masaoka staging system (I: n = 6 [26.1%], IIa: n = 7 [30.4%], IIb: n = 2 [8.7%], III: n = 1 [4.4%], IVa: n = 7 [30.4%]) and the WHO histological classification (A: n = 4 [17.4%], AB: n = 5 [21.7%], B1: n = 1 [4.4%], B2: n = 8 [34.8%], B3: n = 3 [13%], C: n = 2 [8.7%]). Recurrence of thymoma was documented in three (13%) patients. After a mean follow-up of 58.4 months, 21 (91.3%) patients are alive. The overall survival rate was 95% and 87.8%, at 2 and 5 years, respectively. The disease-free interval at 5 years was 85% for the 17 (73.9%) patients with complete resection.

Conclusions Surgical resection of thymoma is the preferred treatment, because it is safe and effective with a low rate of recurrence and a good long-term survival. Advanced and invasive thymomas require a multimodal approach for better local tumor control and further improvement of prognosis.

Keywords

thymoma - thymic carcinoma - thymus hyperplasia - myasthenia gravis

• References

• 1 Detterbeck FC, Parson AM. Thymic tumors. Ann Thorac Surg 2004; 77: 1860-1869
• 2 Masaoka A, Monden Y, Nakahara K , et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-2492
• 3 Rosai J, Sobin L. Histological typing of tumours of the thymus. In: World Health Organization, ed. International histological Classification of Tumours. Heidelberg: Springer Verlag; 1999: 1-16
• 4 Lopez-Cano M, Ponseti-Bosch JM, Espin-Basany E, Sanchez-Garcia JL, Armengol-Carrasco M. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg 2003; 76: 1643-1649
• 5 Drachmann DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797-1810
• 6 Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg 2003; 76: 878-885
• 7 Kattach H, Anastasiadis K, Cleuziou J , et al. Transsternal thymectomy for myasthenia gravis: surgical outcome. Ann Thorac Surg 2006; 81: 305-308
• 8 Okereke IC, Kesler KA, Morad MH , et al. Prognostic indicators after surgery for thymoma. Ann Thorac Surg 2010; 89: 1071-1079
• 9 Hejna M, Haberl I, Raderer M. Nonsurgical management of malignant thymoma. Cancer 1999; 85: 1871-1884
• 10 Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Curr Treatment Options Oncol 2008; 9: 277-287
• 11 Cardillo G, Carleo F, Giunti R , et al. Predictors of survival in patients with locally advanced thymoma and thymic carcinoma (Masaoka stages III and IVa). Eur J Cardiothoracic Surg 2010; 37: 819-823
• 12 Marienhagen J, Schalke B, Aebert H, Held P, Eilles C, Bogdahn U. Somatostatin receptor scintigraphy in thymoma imaging method and clinical application. Pathol Res Pract 1999; 195 (8) 575-581
• 13 Wilkins KB, Sheikh E, Green R , et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999; 230 (4) 562-574
• 14 Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol 1999; 17: 2280-2289
• 15 Rea F, Marulli G, Girardi R , et al. Long-term survival and prognostic factors in thymic epithelial tumours. Eur J Cardiothoracic Surg 2004; 26: 412-418
• 16 Venuta F, Anile M, Diso D , et al. Thymoma and thymic carcinoma. Eur J Cardiothoracic Surg 2010; 37: 13-25
• 17 Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg 2010; 89: 912-917
• 18 Regnard JF, Magdeleinat P, Dromer C , et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996; 112 (2) 376-384
• 19 Lardinois D, Rechsteiner R, Läng RH , et al. Prognostic relevance of Masaoka and Müller-Hermelink classification in patients with thymic tumors. Ann Thorac Surg 2000; 69: 1550-1555
• 20 Margaritora S, Cesario A, Cusumano G , et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010; 89: 245-252
• 21 Kim BK, Cho BC, Choi HJ , et al. A single institutional experience of surgically resected thymic epithelial tumors over 10 years – clinical outcomes and clinicopathologic features. Oncol Reports 2008; 19: 1525-1531
• 22 Ishikawa Y, Matsuguma H, Nakahara R , et al. Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of extrapleural pneumonectomy. Ann Thorac Surg 2009; 88: 952-957
• 23 Refaely Y, Simansky DA, Paley M, Gottfried M, Yellin A. Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 2001; 72: 366-370
• 24 De Bree E, van Ruth S, Baas B , et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480-487
• 25 Hofmann HS, Wiebe K. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion. Chirurg 2010; 81 (6) 557-562